Onkure Therapeutics Inc
OKUR
NASDAQ
Biotechnology
$3.99
USD
+0.09 (+2.31%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $157.94M
Volume 216.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-58.70M
TTM
— YoY
Operating Cash Flow
$-47.84M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.7 | 3.6 | 3.4 | 3.9 | 4.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 16.3 | 15.5 | 14.1 | 15.6 | 16.9 |
Operating Income | -16.3 | -15.5 | -14.1 | -15.6 | -16.9 |
EBITDA | -16.2 | -15.4 | -14.0 | -15.5 | -16.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.9 | 0.8 | 0.6 | 0.5 | 1.6 |
Income Before Income Taxes | -15.4 | -14.7 | -13.5 | -15.2 | -15.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -15.4 | -14.7 | -13.5 | -15.2 | -15.3 |
Consolidated Net Income / Loss | -15.4 | -14.7 | -13.5 | -15.2 | -15.3 |
Net Income Attributable to Common Shareholders | -15.4 | -14.7 | -13.5 | -15.2 | -15.3 |
Basic EPS | -$1.14 | -$1.09 | -$0.99 | -$1.11 | -$0.31 |
Diluted EPS | -$1.14 | -$1.09 | -$0.99 | -$1.11 | -$0.31 |
Basic Shares Outstanding | 13.5M | 13.5M | 13.6M | 13.7M | 49.9M |
Diluted Shares Outstanding | 13.5M | 13.5M | 13.6M | 13.7M | 49.9M |